Research Links Ghrelin and LEAP2 Hormones to Anorexia Nervosa Recovery Challenges
Anorexia nervosa is a serious eating disorder characterized by self-imposed food restriction and often accompanied by hyperactivity, leading to severe undernutrition and a high mortality rate among psychiatric disorders. Despite existing treatments focusing on nutritional rehabilitation and multidisciplinary care, recovery is challenging, with about 40 percent of hospitalized patients being readmitted within six months of discharge. Recent research published in Translational Psychiatry sheds light on the potential role of the hormone ghrelin and its antagonist, LEAP2 (liver-expressed antimicrobial peptide 2), in understanding the metabolic disruptions associated with anorexia nervosa. Neuroscientist Virginie Tolle, who presented the findings at the Federation of European Neuroscience Societies Forum 2026, emphasizes the need for effective treatments for this complex disorder. The study involved 30 women aged 18 to 60 diagnosed with anorexia nervosa, who participated in a four-month refeeding program at a specialized eating disorders center. Blood samples were taken before treatment, after four months, and again six months later to measure levels of ghrelin and LEAP2. Ghrelin is known to signal hunger, but its role in individuals with anorexia may be disrupted. The results revealed that patients had approximately 20 percent higher levels of LEAP2 upon hospitalization, which decreased after treatment as they regained weight. The ghrelin/LEAP2 ratio was found to negatively correlate with impulse control in patients who maintained stable weight gain post-discharge, indicating that those who relapsed had elevated LEAP2 levels. In parallel experiments with mice that had lost weight, researchers observed increased impulsivity in those that had been starved, which only partially improved with refeeding. The findings suggest that hormonal imbalances may contribute to the cycles of relapse that complicate recovery from anorexia nervosa. If these results can be validated in larger studies, they could lead to blood tests identifying patients at risk of relapse and inform the development of new pharmacological treatments. Tolle's research indicates that metabolic signals regulating hunger adapt differently in pathological eating disorders, influencing both brain function and decision-making processes. This study positions LEAP2 as a potential biomarker for relapse and a target for new therapeutic strategies, highlighting the importance of understanding the metabolic and cognitive consequences of food restriction in these patients.




